ToGA Trial Shows Survival Benefit for Trastuzumab in HER2+ Gastric Cancer
Margaret Tempero: ToGA Trial Shows Survival Benefit for Trastuzumab in HER2+ Gastric Cancer
20100001
2010 Jan 1
Top Stories of 2009
ToGA Trial Shows Survival Benefit for Trastuzumab in HER2+ Gastric Cancer
Top Stories of 2009. 2010 Jan 1
Dr. Margaret Tempero is Deputy Director and Director of Research Programs, UCSF Helen Diller Family Comprehensive Cancer Center; and Professor of Medicine, Department of Medicine, University of California, San Francisco. View profile. 1. In your view, which development in gastrointestinal cancer that has occurred in 2009 could have the most significant impact on oncology?I’d have to highlight presentation of the results of the ToGA trial Trastuzumab in Gastric Cancer (ToGA) trial as the most important...